Abstract: Peptides and peptide derivatives of the following general Formula I: (SEQ ID NO: 15) (I) H2N-GHRPX1X2X3X4X5X6X7X8PX9X10X11PX12PPPX13X14X15 X16GYR-X17, wherein: X1-X16 denote one of the 20 genetically encoded amino acids, X17 denotes OR1, with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or different and denoting hydrogen, (C1-C10)-alkyl, or a residue -PEG5-60K, wherein the PEG-residue is linked to the N atom via a spacer, or a residue NH—Y-Z-PEG5-60K, wherein Y denotes a chemical bond or a genetically coded amino acid from among the group of S, C, K or R, and Z denotes a spacer by way of which a polyethylene glycol (PEG)-residue may be linked, as well as the physiologically acceptable salts thereof, or wherein: X15 or X16 denotes an amino acid from the group of C or K, which is linked to a residue Z-PEG5-60K via the heteroatom in the side chain, and wherein X17 denotes OR1, with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or

Abstract: A method screens compounds out of the group consisting of proteins, peptides, peptidomimetics, antibodies and small organic molecules that increase the activity of the protein Rac1 by virtue of their binding to the extracellular portion of this protein. The method includes the steps of: contacting a confluent layer of cultured endothelial cells with at least one of test compounds, lysing the endothelial cells with a lysation buffer, and measuring the amount of Rac1 activity.

Abstract: The invention relates to peptides and peptide derivatives of the following general Formulas (Ia) and (Ib) as well as in particular anti-inflammatory drugs containing these peptides.

Abstract: The invention is concerned with the use of a peptide comprising the N-terminal sequence Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala- Pro-Ser-Leu-Arg-Pro-Ala-Pro-Pro-Pro-Ile-Ser-Gly- Gly-Gly-Tyr-Arg or any allelic variant or derivative of said peptide possessing the biological property of matching the inducible VE-cadherin binding motif on the B?-chain (i.e. B?15-42) of human fibrin for the preparation of a pharmaceutical preparation for the treatment of shock, more specifically of hemorrhagic shock.

Abstract: Peptides and peptide derivatives of the following general Formula I: H2H-GHRPX1X2X3X4X5X6X7X8X9X10- (I) X11PX12PPPX13X14X15X16GYR-X17, wherein: X1-X16 denote one of the 20 genetically encoded amino acids, X17 denotes OR1, with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or different and denoting hydrogen, (C1-C10)-alkyl, or a residue -PEG5-60K, wherein the PEG-residue is linked to the N atom via a spacer, or a residue NH—Y-Z-PEG5-60K, wherein Y denotes a chemical bond or a genetically coded amino acid from among the group of S, C, K or R, and Z denotes a spacer by way of which a polyethylene glycol (PEG)-residue may be linked, as well as the physiologically acceptable salts thereof, or wherein: X15 or X16 denotes an amino acid from the group of C or K, which is linked to a residue Z-PEG5-60K via the heteroatom in the side chain, and wherein X17 denotes OR1, with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or different and denoting hydrog

Abstract: The invention relates to peptides and peptide derivatives of the following general Formulas Ia and Ib as well as in particular anti-inflammatory drugs containing these peptides.

Abstract: Goniochromatic luster pigments comprising at least one dielectric low-refractive interference-colored layer which includes a polar organic solvent which can interact with the layer material via functional groups.

Abstract: Goniochromatic luster pigments comprising at least one dielectric low-refractive interference-colored layer which includes a polar organic solvent which can interact with the layer material via functional groups.

Abstract: The present invention relates to the use of pteridine derivatives of the formula I in which X is O or NH and R4, for example, is hydrogen, phenyl or the radical R4a—CH2— and R4a, for example, is hydrogen, (C1-C4)-alkylmercapto, the radical —NR11R12 or the radical —OR13, and in which R1, R2, R3, R5, R6, R7, R11, R12 and R13 have the meanings given in claim 1, which are nitric oxide synthase inhibitors, for the treatment of diseases which are caused by an increased nitric oxide level.

Abstract: The present invention relates to the use of pteridine derivatives of the formula I ##STR1## in which X is O, NH or N--(C.sub.1-C.sub.5)-alkanoyl, R.sup.3 is the radical --OR.sup.4, --NR.sup.5 R.sup.6 or --S(O).sub.m R.sup.7, and R, R.sup.1, R.sup.2, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and m have the meanings given in claim 1, which are nitric oxide synthase inhibitors, for the treatment of diseases which are caused by an increased nitric oxide level.

Abstract: The invention relates to a method of treating cardiac insufficiency by using compounds of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 are identical or different and each denote hydrogen or an organic radical and R.sup.4 and R.sup.5, together with the atoms carrying them, form a mono-, bi- or tri-cyclic heterocyclic ring system. The invention furthermore relates to compounds of the formula I and agents containing these for use in the treatment of the abovementioned disease.

Abstract: The invention relates to a method of treating cardiac insufficiency by using compounds of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 are identical or different and each denote hydrogen or an organic radical and R.sup.4 and R.sup.5, together with the atoms carrying them, form a mono-, bi- or tri-cyclic heterocyclic ring system. The invention furthermore relates to compounds of the formula I and agents containing these for use in the treatment of the abovementioned disease.

Abstract: The invention relates to combinations of angiotensin-converting enzyme inhibitors with calcium antagonists, processes for their preparation and their use as medicaments.

Abstract: The invention relates to a method of treating cardiac insufficiency by using compounds of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 are identical or different and each denote hydrogen or an organic radical and R.sup.4 and R.sup.5, together with the atoms carrying them, form a mono-, bi- or tri-cyclic heterocyclic ring system. The invention furthermore relates to compounds of the formula I and agents containing these for use in the treatment of the abovementioned disease.

Abstract: Imidazole derivatives with a biphenylsulfonylurea or biphenylsulfonylurethane side chain, process for their preparation and their useCompounds of the formula (I) ##STR1## in which R.sup.1 is, for example, ethyl,R.sup.2 is, for example, methyl,n is, for example, zero,R.sup.3 is, for example, COOH, andR.sup.4 is, for example, SO.sub.2 NHCONHCH.sub.3are highly active antagonists of angiotensin II receptors.

Abstract: The invention relates to compounds of the formula I ##STR1## in which n is 1, 2 or 3,Z.sup.1 and Z.sup.2, and Z.sup.3 and Z.sup.4, in each case together represent a chemical bond orZ.sup.1, Z.sup.2, Z.sup.3 and Z.sup.4 in each case represent hydrogen,Z.sup.1 and Z.sup.2 being in the cis configuration relative to one another and the COR.sup.1 group on C atom 3 being in the endo configuration relative to the bicyclic ring system,R.sup.1 denotes hydroxyl, alkoxy, aralkoxy, amino, alkylamino or dialkylamino andR.sup.2 denotes hydrogen, alkyl, aryl, aralkyl, cycloalkyl or alkylcycloalkyl,processes for their preparation and their use.

Abstract: The invention relates to compounds of the formula ##STR1## in which X, Y and Z are identical or different and are N or CR.sup.2, L is an alkylene radical, q is 0 or 1, and A is the radical of a fused heterobicyclic compound. The invention furthermore relates to a process for preparing the said compounds, agents containing these, and the use thereof for angiotensin II receptors.

Abstract: The invention relates to a method of treating cardiac insufficiency by using compounds of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 are identical or different and each denote hydrogen or an organic radical and R.sup.4 R.sup.5, together with the atoms carrying them, form a mono-, bi- or tri-cyclic heterocyclic ring system. The invention furthermore relates to compounds of the formula I and agents containing these for use in the treatment of the abovementioned disease.

Abstract: Aminoacid derivatives of the formula I ##STR1## A , n, R.sup.1, R.sup.2 and R.sup.3 have the meanings given, and salts thereof, a process for their preparation, pharmaceutical preparations based on these compounds, and their use as medicaments.

Abstract: Amino acid derivatives with renin-inhibiting properties, a process for the preparation thereof, agents containing these, and the use thereofThe invention relates to renin-inhibiting amino acid derivatives of the formula ##STR1## in which R.sup.1 is a radical of a substituted nitrogen-containing heterocycle such as piperidine, X is CO, CS, SO.sub.2 or SO, Y is CH.sub.2, O or S, B is the radical of an amino acid of the formula H--B--OH, and R.sup.3, R.sup.4 and R.sup.5 are as defined in the description, a process for the preparation thereof, agents containing these, and the use thereof.